IMNM vs RCUS

For growth investors, Arcus Biosciences, Inc.

(RCUS) is the stronger pick with -4. 3% revenue growth year-over-year, versus -23. 2% for Immunome, Inc. (IMNM). Analysts rate Immunome, Inc. (IMNM) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunome, Inc.

(IMNM) delivered a total return of +1. 0%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: IMNM returned +65. 0% versus RCUS's +45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcus Biosciences, Inc.

(RCUS) is the lower-risk stock at 1. 95β versus Immunome, Inc. 's 2. 08β — meaning IMNM is approximately 6% more volatile than RCUS relative to the S&P 500. On balance sheet safety, Immunome, Inc. (IMNM) carries a lower debt/equity ratio of 1% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcus Biosciences, Inc.

(RCUS) is pulling ahead at -4. 3% versus -23. 2% for Immunome, Inc. (IMNM). On earnings-per-share growth, the picture is similar: Immunome, Inc. grew EPS 51. 4% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcus Biosciences, Inc.

(RCUS) is the more profitable company, earning -142. 9% net margin versus -30. 6% for Immunome, Inc. — meaning it keeps -142. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCUS leads at -156. 3% versus -32. 3% for IMNM. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcus Biosciences, Inc.

(RCUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Immunome, Inc. (IMNM) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCUS: +45. 9%, IMNM: +65. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.